Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 367
Gene Symbol: AR
AR
0.100 AlteredExpression disease BEFREE ZEB1 suppression by stably transfecting shRNA in a triple negative breast cancer cell line resulted in a decrease of AR mRNA, protein, and AR downstream targets. 19921427 2010
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE A meta-analysis of public gene expression databases indicated that ACSL4 expression is positively correlated with a unique subtype of triple negative breast cancer (TNBC), characterized by the absence of androgen receptor (AR) and therefore referred to as quadruple negative breast cancer (QNBC). 24155918 2013
Entrez Id: 367
Gene Symbol: AR
AR
0.100 AlteredExpression disease BEFREE The TNBC subgroup that predicted to have relatively favorable prognosis was characterized by high expression of "luminal-like" genes [androgen-receptor (AR) and GATA3], whereas the subgroup with worse prognosis was characterized by expression of cancer stem-cell markers. 23549873 2013
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Silencing BAG3 reduced Mcl-1 protein levels and overcame ABT-737 resistance in several of the cell lines, including triple-negative breast cancer (MDA-MB231) and androgen receptor-negative prostate cancer (PC3) cells. 23341456 2013
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE In subgroup analysis, AR could predict DFS outcome in estrogen receptor (ER) positive (HR 0.45, 95% CI 0.34-0.59), ER negative (HR 0.42, 95% CI 0.26-0.67), and triple negative breast cancer (HR 0.40, 95% CI 0.23-0.69). 24324816 2013
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Therefore, in this study, we analyzed the status of AR in combination with androgen synthesizing enzymes (5α-reductase type 1 (5αR1) and 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5)] in order to further understand androgenic actions in TNBC. 23373898 2013
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE SARMs may provide promise as novel targeted therapies to treat AR-positive triple-negative breast cancer. 25072326 2014
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE To further substantiate our hypothesis and provide mechanistic insights, we also looked at the expression and regulation of these factors in publically available microarray data and in a panel of TNBC AR-positive cell lines. 24715382 2014
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Androgen receptor has been associated with triple negative breast cancer pathogenesis, but its role in the different subtypes has not been clearly defined. 24505496 2014
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Previously, we identified a TNBC subtype that has a luminal phenotype and expresses the androgen receptor (AR+). 25103565 2014
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE However little is known in TNBC about how the AR is modulated by these mechanisms and the potential therapeutic strategists to inhibit its expression. 24779793 2014
Entrez Id: 367
Gene Symbol: AR
AR
0.100 GeneticVariation disease BEFREE Further subtype analysis of TNBCs showed the highest amplification rate (42%) in the basal-like 1 subtype and the lowest amplification rate (9%) in the luminal androgen receptor subtype. 26172299 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 AlteredExpression disease BEFREE In contrast, the expression level of AR was lower in TNBC than non-TNBC (OR = 0.07, P < 0.00001). 25695063 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Additionally, the presence of PIK3CA mutations of cfDNA was significantly correlated with positive androgen receptor phosphorylated form depending on PI3K signaling pathway (pAR) which is independent favorable prognostic factors of TNBC. 26353837 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 AlteredExpression disease BEFREE Higher AR expression levels in TNBC predicted for lower Ki-67 levels. 26051240 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 AlteredExpression disease BEFREE Our data suggest that the combination of AR and E-cadherin expression as well as Ki-67 status might be useful prognostic markers in TNBC. 26039245 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Together, our findings indicate that non-LAR subtypes of TNBC are AR dependent and, moreover, that enzalutamide is a promising targeted therapy for multiple molecular subtypes of AR(+) TNBC. 25713333 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Therefore, we strongly support the routine assessment of AR in TNBC, and preferably in all breast carcinomas. 25310144 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Here, we review the literature on AR in TNBC and propose that TNBC be further sub-classified as either AR+ TNBC or quadruple negative breast cancer since targeting AR may represent a viable therapeutic option for a subset of TNBC. 26201402 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 AlteredExpression disease BEFREE To this end, we define five potential clinically actionable groupings of TNBC: 1) basal-like TNBC with DNA-repair deficiency or growth factor pathways; 2) mesenchymal-like TNBC with epithelial-to-mesenchymal transition and cancer stem cell features; 3) immune-associated TNBC; 4) luminal/apocrine TNBC with androgen-receptor overexpression; and 5) HER2-enriched TNBC. 25973541 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 GeneticVariation disease BEFREE We identified and confirmed four distinct TNBC subtypes: (i) luminal androgen receptor (AR; LAR), (ii) mesenchymal (MES), (iii) basal-like immunosuppressed (BLIS), and (iv) basal-like immune-activated (BLIA). 25208879 2015
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE We demonstrated that combination of AR antagonist (bicalutamide) and PARP inhibitor (ABT-888) could inhibit cell viability and induce cell apoptosis significantly whatever in vitro or in vivo setting in AR-positive TNBC. 27994514 2016
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Numerous experimental approaches are under way, and several encouraging drug classes, such as immune checkpoint inhibitors, poly(ADP-ribose) polymerase inhibitors, platinum agents, phosphatidylinositol-3-kinase pathway inhibitors, and androgen receptor inhibitors, are being investigated in TNBC. 27401886 2016
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE We demonstrate that AR agonist DHT induces MSL TNBC breast cancer cells proliferation and inhibits apoptosis in vitro. 26938985 2016
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE The aim of this study was to assess the combined immunohistochemical expression of CK 5/6, AR, and p53 as a potential prognostic marker of adjuvant chemotherapy for patients with TNBC. 26009308 2016